cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

By rosaguerrero • May 2, 2022

Li S, Zeng W, Ni X, Zhou Y, Stackpole ML, Noor ZS, Yuan Z, Neal A, Memarzadeh S, Garon EB, Dubinett SM, Li W, Zhou XJ. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 May 2;28(9):1841-1853. doi: 10.1158/1078-0432.CCR-21-1242. PMID: 35149536; PMCID: PMC9126584.

Tags: Hematology/Oncology, Publications

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]

Alcohol and cannabis use associated with cardiometabolic biomarkers among “All of Us” cancer survivors

Arizpe A, Chapman TM, Rodriguez C, Carvajal A, Queen KJ, Navarro S, Ochoa-Dominguez CY, Kim SE, Toledo-Corral CM, Farias AJ. Alcohol and cannabis use associated[...]

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment[...]